Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors

@article{Baumann1996PharmacokineticPharmacodynamicRO,
  title={Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors},
  author={Pierre Baumann},
  journal={Clinical Pharmacokinetics},
  year={1996},
  volume={31},
  pages={444-469}
}
  • P. Baumann
  • Published 1 December 1996
  • Medicine, Biology
  • Clinical Pharmacokinetics
SummaryThe recently introduced antidepressants, the selective serotonin reuptake inhibitors (SSRIs) [citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline], are known for their clinical efficacy, good tolerability and relative safety. They differ from each other in chemical structure, metabolism and pharmacokinetic properties. Therapeutic drug monitoring of these compounds is not widely used, as the plasma concentration ranges within which clinical response with minimal adverse effects… 

Pharmacokinetics of selective serotonin reuptake inhibitors.

Metabolism and Pharmacokinetics of Selective Serotonin Reuptake Inhibitors

  • C. DeVane
  • Biology, Medicine
    Cellular and Molecular Neurobiology
  • 2004
TLDR
The metabolism and relevant pharmacokinetic properties of the SSRIs are summarized, appearing to share similar pharmacodynamic properties which translate to efficacy in the treatment of depression and anxiety syndromes.

Metabolic drug interactions with new psychotropic agents

TLDR
The potential for metabolically based drug interactions of any new psychotropic agent may be anticipated on the basis of knowledge about the CYP enzymes responsible for its metabolism and about its effect on the activity of these enzymes.

Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review

Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?

TLDR
In several studies there has not been found a clear relationship between clinical efficacy and plasma concentration, nor any threshold that defines toxic concentrations, so therapeutic drug monitoring (TDM) of the SSRIs may be useful mainly in situations where poor compliance is suspected and when therapeutic failure or toxic events are experienced at clinically relevant dosages.

Stereoselective HPLC-assay for citalopram and its metabolites.

TLDR
The present assay allows a rapid, sensitive, and reliable stereoselective determination of CIT and its (active) metabolites which can be applied for assessing pharmacokinetic parameters and evaluating putative relationships to clinical (side) effects.

Metabolism of the Newer Antidepressants

  • S. Caccia
  • Biology, Medicine
    Clinical pharmacokinetics
  • 1998
TLDR
Several chemically unrelated agents has been developed and introduced in the past decade, to supplement the earlier antidepressants, as well as drugs with distinct neurochemical profiles such as mirtazapine, nefazodone, moclobemide and tianeptine, which may explain the individual variability with all these drugs.

Clinical Uses and Differences Among the Selective Serotonin Reuptake Inhibitors

TLDR
The selective serotonin reuptake inhibitors are the most commonly prescribed agents for treating depressive disorders in the United States and have a different pharmacodynamic and tolerability profile from other antidepressants.

The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy

TLDR
Systematic review of the literature revealed for new and old antidepressant drugs that drug and metabolite concentrations in blood are measures of the pharmacokinetic phenotype and related differentially to occupancy of primary target structures, therapeutic effects and unwanted anticholinergic, cardiac and other side effects.
...

References

SHOWING 1-10 OF 164 REFERENCES

Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror

TLDR
It is concluded that for routine therapeutic drug monitoring, the plasma level measurement of the enantiomers of citalopram and fluoxetine is probably of little relevance, but for the study of the structure-activity relationship between these drugs and the cerebral 5-HT transporter, the stereochemical differences of these enantiomer should be considered.

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

  • S. Preskorn
  • Medicine, Biology
    Clinical pharmacokinetics
  • 1997
TLDR
An overview of the clinically relevant pharmacology of selective serotonin reuptake inhibitors (SSRIs) with an emphasis on their pharmacokinetics and effects on cytochrome P450 (CYP) enzymes is presented.

Overview of the Pharmacokinetics of Fluvoxamine

TLDR
Fluvoxamine pharmacokinetics are substantially unaltered by increased age or renal impairment, however, its elimination is prolonged in patients with hepatic cirrhosis, and has the potential for clinically significant drug interactions.

Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline

  • S. Preskorn
  • Medicine
    International clinical psychopharmacology
  • 1994
TLDR
Sertraline is notable for having few clinically meaningful drug interactions at its usually effective, minimum dose, and at their usually effective minimum dose can inhibit the hepatic isoenzyme CYP2D6, which is important in the oxidative metabolism of a variety of drugs.

Pharmacokinetic Optimisation of Therapy with Newer Antidepressants

  • P. Goodnick
  • Medicine, Biology
    Clinical pharmacokinetics
  • 1994
TLDR
The antidepressants best suited for pharmacokinetic optimisation of therapy are the following: desipramine, sertraline, fluvoxamine, citalopram and amfebutamone, which stands out as having the best effects on behaviour among all antidepressants.

Clinical Pharmacokinetics of Fluvoxamine

TLDR
Fluvoxamine pharmacokinetics are substantially unaltered in the elderly, whereas higher plasma drug concentrations (relative to dose) are observed in patients with alcoholic cirrhosis of the liver, and preliminary data suggest that plasmaDrug concentrations may increase non-linearly with increasing daily dosage.

Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents

TLDR
In patient management, it is important to consider the fact that most antidepressants can also act as enzyme inhibitors, which have the potential of causing drug interactions and can be minimized or avoided by following simple clinical logic.

Clinical Pharmacokinetics of Fluoxetine

TLDR
There appears to be a therapeutic window for fluoxetine, and the pharmacokinetics of this drug are not affected by either obesity or renal impairment, which makes this drug particularly suitable for use in elderly patients with depression.

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

TLDR
It is suggested that compounds with SSRI activity are likely to interact with human CYP2D6 in vivo with the potential of causing drug interactions.

The emerging role of cytochrome P450 3A in psychopharmacology.

TLDR
Knowing the substrates, inhibitors, and inducers of CYP3A3/ and other cytochrome P450 isoforms may help clinicians to anticipate and avoid pharmacokinetic drug interactions and improve rational prescribing practices.
...